GROWTH OPPORTUNITIES IN ANTIBIOTIC-FREE PROTEIN EXPRESSION SYSTEMS, MICROBIOME, PRECISION NUTRITION, AND IMMUNE PROFILING

GROWTH OPPORTUNITIES IN ANTIBIOTIC-FREE PROTEIN EXPRESSION SYSTEMS, MICROBIOME, PRECISION NUTRITION, AND IMMUNE PROFILING

RELEASE DATE
16-Oct-2020
REGION
Global
Research Code: D759-00-19-00-00
SKU: HC03349-GL-TA_24864

$950.00

Special Price $807.50 save 15 %

In stock
SKU
HC03349-GL-TA_24864

$950.00

$807.50 save 15 %

DownloadLink

Pay by invoice

ENQUIRE NOW

Description

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) consists insights across various antibiotic-free microbial protein expression systems, Immune profiling platforms, microbial therapeutics, and targeted antibacterials such as fecal microbiota transplantation and microbial skincare, phage therapy, venom as antimicrobial, novel antibiotic absorbent, and single-cell genomics platform for the microbiome. Further, it discusses point-of-care rapid diagnostic platforms for COVID-19, novel radioisotope therapy for cancer, precision nutrition, and manufacturing of clinical-grade cannabinoid.

The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms.

The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.

Keywords: Food-as-medicine, diabetes, neonatal microbiome, gut microbiome, premature babies, precision nutrition, Sports Genomics, probiotic, functional foods, point-of-care in vitro diagnostic, immunoassay, radioisotopes, Radiopharmaceuticals, AI-based genomic analysis, RNA therapeutics, small activating RNA, lab-grown meat, phage therapy, COVID-19 diagnostic, point-of-care sweat test, gut-brain microbiome, cannabinoid, Single Cell Genomics, antibiotic-free microbial protein expression systems, immune profiling, antibiotic absorbent, gut microbiota restoration therapy, antimicrobial venom, microbiome therapeutics

Table of Contents

INNOVATIONS IN LIFE SCIENCES, HEALTH & WELLNESS

  • ENGENE BIOTECH GMBH, AUSTRIA
  • GROWTH OPPORTUNITIES
  • PROFACGEN, US
  • GROWTH OPPORTUNITIES
  • FUJIFILM DIOSYNTH BIOTECHNOLOGIES, UK
  • GROWTH OPPORTUNITIES
  • WACKER CHEMIE AG, GERMANY
  • GROWTH OPPORTUNITIES
  • IMMUNAI, US
  • GROWTH OPPORTUNITIES
  • ADAPTIVE BIOTECHNOLOGIES, US
  • GROWTH OPPORTUNITIES
  • DA VOLTERRA, FRANCE
  • GROWTH OPPORTUNITIES
  • ARMATA PHARMACEUTICALS INC., US
  • GROWTH OPPORTUNITIES
  • REBIOTIX INC., US
  • GROWTH OPPORTUNITIES
  • UNIVERSITY OF PENNSYLVANIA, US
  • GROWTH OPPORTUNITIES
  • PICODYA, ISRAEL
  • GROWTH OPPORTUNITIES
  • MRM HEALTH N.V, BELGIUM
  • GROWTH OPPORTUNITIES
  • RAYZEBIO, US
  • GROWTH OPPORTUNITIES
  • SOPHIA GENETICS, NETHERLANDS
  • GROWTH OPPORTUNITIES
  • MOSA MEAT, NETHERLANDS
  • GROWTH OPPORTUNITIES
  • BIOMX, ISRAEL
  • GROWTH OPPORTUNITIES
  • ASTARTE MEDICAL, US
  • GROWTH OPPORTUNITIES
  • FITBIOMICS, US
  • GROWTH OPPORTUNITIES
  • DAY TWO, ISRAEL
  • GROWTH OPPORTUNITIES
  • LEUCINE RICH BIO, INDIA
  • GROWTH OPPORTUNITIES
  • SANOBIOTEC, LITHUANIA
  • GROWTH OPPORTUNITIES
  • BITBIOME, JAPAN
  • GROWTH OPPORTUNITIES
  • INNOVATIVE GENOMICS INSTITUTE, US
  • GROWTH OPPORTUNITIES
  • KALLYOPE, USA
  • GROWTH OPPORTUNITIES
  • DETACT DIAGNOSTICS BV, NETHERLANDS
  • GROWTH OPPORTUNITIES
  • INTELLIGENT FINGERPRINTING, UK
  • GROWTH OPPORTUNITIES

KEY CONTACTS

  • KEY CONTACTS
  • KEY CONTACTS
  • KEY CONTACTS
  • KEY CONTACTS
  • KEY CONTACTS
  • KEY CONTACTS
  • KEY CONTACTS
  • LEGAL DISCLAIMER
Related Research
This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) consists insights across various antibiotic-free microbial protein expression systems, Immune profiling platforms, microbial therapeutics, and targeted antibacterials such as fecal microbiota transplantation and microbial skincare, phage therapy, venom as antimicrobial, novel antibiotic absorbent, and single-cell genomics platform for the microbiome. Further, it discusses point-of-care rapid diagnostic platforms for COVID-19, novel radioisotope therapy for cancer, precision nutrition, and manufacturing of clinical-grade cannabinoid. The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Food-as-medicine, diabetes, neonatal microbiome, gut microbiome, premature babies, precision nutrition, Sports Genomics, probiotic, functional foods, point-of-care in vitro diagnostic, immunoassay, radioisotopes, Radiopharmaceuticals, AI-based genomic analysis, RNA therapeutics, small activating RNA, lab-grown meat, phage therapy, COVID-19 diagnostic, point-of-care sweat test, gut-brain microbiome, cannabinoid, Single Cell Genomics, antibiotic-free microbial protein expression systems, immune profiling, antibiotic absorbent, gut microbiota restoration therapy, antimicrobial venom, microbiome therapeutics
More Information
No Index No
Podcast No
Industries Healthcare
WIP Number D759-00-19-00-00
Is Prebook No
Ti Codes D759